TD Cowen Maintains Buy on TransMedics Gr, Raises Price Target to $175
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joshua Jennings maintains a Buy rating on TransMedics Group (NASDAQ:TMDX) and raises the price target from $130 to $175.
June 07, 2024 | 4:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen analyst Joshua Jennings maintains a Buy rating on TransMedics Group and raises the price target from $130 to $175.
The raised price target from $130 to $175 by TD Cowen indicates strong confidence in TransMedics Group's future performance, likely leading to positive short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100